OssiaLabs Bone Health Formula
OSSTIVIA
Osstivia is a liquid formulation by OssiaLabs built around Fructus Ligustri Lucidi (FLL) and SNEDDS nano-delivery. This page organizes published research on bone-metabolism pathways, constituent compounds, formulation science, and reported clinical measurements.
3X
Concentrated Extract
6+
Pathway Targets
SNEDDS
Nano-Delivery System
The pathway atlas
A connected view of the science.
Explore the pathways.
Follow the connections.
PATHWAY NETWORK
Click nodes for mechanism detail
Filter
Ctrl + scroll to zoom Click nodes to explore
Delivery System
SNEDDS DELIVERY RESEARCH
SNEDDS formulations are designed to disperse lipophilic compounds into fine droplets after contact with gastrointestinal fluids. The research below presents particle formation, dissolution behavior, intestinal transport pathways, and pharmacokinetic measurements used to characterize this delivery system.
01
Nano-Emulsification
In formulation studies, SNEDDS formed lipid droplets under 200 nm upon contact with gastrointestinal fluid, increasing the interfacial surface area available for dissolution.
02
P-gp Inhibition
SNEDDS research examines how formulation surfactants interact with P-glycoprotein efflux transporters involved in intestinal transport.
03
Lymphatic Transport
Lipid nano-droplets can be incorporated into chylomicrons and transported through intestinal lymphatic pathways, altering exposure to hepatic first-pass metabolism.
04
Systemic Exposure
Pharmacokinetic studies of SNEDDS measure dissolution, absorption, and plasma exposure relative to conventional oral formulations.
SNEDDS self-nanoemulsification mechanism: spontaneous formation of oil-in-water nano-droplets (<200 nm) upon GI contact, increasing interfacial surface area relative to a conventional capsule
SNEDDS advantages over conventional oral delivery: enhanced solubility, dissolution rate, mucosal permeation, P-gp efflux inhibition, and lymphatic transport and their relationship to oral bioavailability
SNEDDS nano-droplet characterization: particle size distribution, zeta potential stability, and dissolution profile in simulated GI fluid demonstrating rapid self-emulsification
Ternary phase diagram for SNEDDS formulation optimization: oil/surfactant/co-surfactant ratios defining the self-emulsification region and nano-droplet formation boundary
Self-double-emulsifying nanoparticle structure: oil-core and water phases stabilized by hydrophilic and lipophilic emulsifier shells; the figure maps nano-droplet formation and intestinal transport of lipophilic compounds
Free drug and SNEDDS intestinal-dispersion comparison: the figure contrasts conventional capsule dispersion with lipid nano-droplets at the intestinal epithelium
Molecular Mechanisms
BIOLOGICAL PATHWAYS
The FLL literature describes activity across several pathways involved in bone remodeling. The sections below summarize reported findings from cellular, animal, and human research.
Important: FLL studies commonly assess biological responses across defined doses and treatment durations. The findings below are organized by pathway and cited source.
01 Bone Formation
Wnt/beta-catenin and BMP-Smad Signaling
In the cited experimental models, FLL compounds were associated with increased Wnt and BMP-2 signaling alongside expression of RUNX2 and Osterix (Osx), transcription factors involved in osteoblast differentiation and bone-matrix formation.
Kong et al. Bioengineered. 2022;13:10640
Chen et al. Molecules. 2017;22:1469
02 Inhibiting Bone Breakdown
OPG/RANKL/RANK Axis
The cited studies reported changes in the OPG/RANKL system, including higher OPG and lower RANKL signaling, together with reduced markers of osteoclast differentiation through NF-kB and MAPK pathways.
Xu et al. Mol Med Reports. 2016;14:4767
Tang et al. Chin Med. 2020;15:87
03 Cell Survival and Oxidative Protection
PI3K/Akt Pathway and Antioxidant Defense
Experimental studies reported PI3K/Akt and Nrf2/HO-1 pathway activity, markers associated with osteoblast survival, oxidative-stress response, and apoptosis regulation.
Li et al. Aging (Albany NY). 2019;11:9348
04 Mineralization Environment
Calcium Homeostasis (TRPV6/VDR)
The cited research evaluated FLL-associated changes in PTH/VDR signaling and TRPV6 expression, pathways involved in calcium transport and mineralization.
Chen et al. J Ethnopharmacol. 2021;279:114348
05 Compound-Level Research
Ursolic Acid, Oleanolic Acid, Salidroside
FLL contains ursolic acid, oleanolic acid, and salidroside. The cited studies examine their relationships with IGF-1/PI3K/mTORC1 and other signaling pathways involved in muscle and metabolic physiology.
Wal et al. Russ J Bioorg Chem. 2025;51:1
Feng et al. Front Immunol. 2025;16
Phytochemistry
ACTIVE COMPOUNDS
Fructus Ligustri Lucidi contains a rich array of bioactive triterpenes, iridoids, and phenylpropanoids. Osstivia standardizes these to HPLC-verified concentrations.
Oleanolic Acid
15-20% by HPLC
Hepatoprotective, inhibits PPARgamma to suppress BMSC adipogenesis in favor of osteoblastic differentiation. Activates Nrf2/ARE cytoprotection.
Ursolic Acid
Natural Triterpene
Activates BMP/Smad signaling in BMSCs, suppresses NF-kB and pro-inflammatory cytokines, reprograms macrophages from M1 to M2 phenotype.
Salidroside
Elite Adaptogen
Activates AMPK/Sirt1/PGC-1alpha for mitochondrial resilience, blocks Abeta aggregation, modulates HPA axis to reduce cortisol-mediated bone loss.
Oleuropein / Echinacoside
Iridoid Glycosides
Potent antioxidants and anti-inflammatory agents that complement the triterpene fraction. Echinacoside promotes osteoblast proliferation and ALP activity.
Nuzhenide
Secoiridoid Glycoside
Regulates gut microbiota diversity and increases SCFA production. Supports systemic calcium balance via PTH/VDR axis modulation.
Specnuezhenide
Secoiridoid Glycoside
Modulates SIRT6 expression, linked to NAD-dependent anti-aging pathways and NF-kB suppression in bone tissue.
Frontiers in Pharmacology 2024: FLL phytochemistry, pharmacology, and bioavailability overview diagram
Empirical Data
THE RESEARCH
Peer-reviewed studies have examined FLL in relation to bone formation, resorption, calcium handling, and Sirt6/NF-kB/Cathepsin K signaling. The figures and cited results below summarize those reported observations.
GO:0071363
Cellular Response to Growth Factor Stimulus
In the cited analysis, "cellular response to growth factor stimulus" appeared among enriched biological-process terms. The authors mapped this term to genes involved in IGF-1, TGF-β, and BMP-2 signaling.
NEW MECHANISM
FLL, Sirt6, NF-kB, Cathepsin K Axis
In the cited experimental model, FLL treatment was associated with higher Sirt6 expression, lower acetylated NF-kB p65, and lower Cathepsin K. These markers were analyzed as part of a proposed Sirt6/NF-kB/Cathepsin K pathway related to osteoclast activity.
Reduced RANKL-induced osteoclastogenesis and NFATc1 activity in the cited model
Wnt/beta-catenin, DKK1, SOST, and osteoblast markers measured in the cited studies
Dose-group BMD values reported (high-dose: 0.32 g/cm2 vs control 0.26)
Calcium absorption and retention rates reported with p less than 0.01
Epiphyseal growth-plate cartilage thickness reported 24% to 32% higher in the cited model
GO:0071363 enrichment: cellular response to growth-factor stimulus (IGF-1, TGF-beta)
FLL multi-pathway mechanism: three convergent axes: (1) PTH/CaSR/VDR calcium regulation, (2) ERα/RANKL/OPG/MAPK/Akt osteoclast suppression, (3) Nox4/ROS/NF-κB antioxidant control, inhibiting osteoclastogenesis and promoting osteoblastogenesis
FLL bioactive compound library: 14 pharmacologically active molecules, triterpenoids (oleanolic acid, ursolic acid), iridoid glycosides (nuzhenide through oleoside esters), phenylethanoid glycoside (salidroside), and phenols (hydroxytyrosol, tyrosol, tyrosyl acetate)
Morris water maze: FLL restores spatial memory and learning in aging mice, significantly more platform crossings, greater target zone dwell time, and reduced escape latency vs. aging controls (swim paths and bar charts, Normal/Aging/VE/FLL groups)
FLL articular cartilage protection: H&E (10×) and Safranin-O/glycosaminoglycan staining (10× & 20×) showing FLL preserves cartilage proteoglycan matrix in aging. IOD values quantified across Normal/Aging/VE/FLL groups
FLL suppresses NF-κB p65 acetylation and Cathepsin K in aging bone: IHC (20×/40×) and western blot showing FLL reduces Acetyl-NF-κB-p65 (Lys310) and Cathepsin K protein in osteoclast-rich bone tissue (Normal/Aging/Aging+FLL)
FLL 3D microCT and biomechanics: 3D bone reconstruction with dose-dependent improvements in trabecular parameters (BV/TV, Tb.N, Tb.Sp, Tb.Th) and cortical metrics (Ct.Ar, Ct.Th), plus whole-bone mechanical strength (ultimate load, bending strength, elastic modulus)
FLL upregulates Sirt6 in brain neurons and bone tissue: DAB immunostaining in hippocampal neurons (top panels) and osteoblasts (bottom panels), confirmed by western blot; FLL also restores serum IL-2 and reduces TNF-α in aging (Normal/Aging/Aging+FLL)
FLL dual mechanism pathway diagram: D-gal+NaNO2 induces gut flora dysbiosis → FMO3 → TMAO → oxidative stress; FLL blocks this via Sirt6 upregulation → NF-κB-p65 suppression → Cathepsin K reduction, protecting both bone (↓senile osteoporosis) and brain (↓cognitive deficit)
Ursolic acid (FLL triterpenoid) macrophage mechanism: inhibits LPS/TLR-4 → M1 macrophage activation, balances M1/M2 polarization, induces autophagy, systemic protection of brain (Alzheimer/depression/ischemia), bone (osteoporosis), blood vessels (atherosclerosis), liver, and skin
Ursolic acid immunological network: macrophage M1/M2 polarization balance (TNF-α/IL-6 → IL-10/TGF-β), LPS/TLR-4/NF-κB/pSTAT1/MAPK suppression, autophagy induction, mechanistic links to osteoporosis (osteoclast MAPK/JNK), Alzheimer/depression, liver fibrosis, atherosclerosis
Ursolic acid multi-organ body map: brain (Alzheimer/neuritis via ROS/NF-κB/NLRP3 in microglia), bone (osteoporosis via JNK/MAPK/TLR/NF-κB osteoclast differentiation), blood vessels (atherosclerosis via NOX4/NF-κB), liver (fibrosis via Kupffer/NLRP3 pyroptosis), skin (wound healing)
Ursolic acid five-organ radial effects: bone (inhibit osteoclast differentiation), skin (inflammation regulation, wound healing), blood vessels (autophagy promotion, foam cell restriction), brain (neuroinflammatory regulation, neuroprotection), liver (fibrosis regulation, immune surveillance)
Ursolic acid broad pharmacological profile: 11 documented bioactivities, antifungal, antimalarial, antihistaminic, cardioprotective, anti-inflammatory, anticancer, antioxidant, antidiabetic, antibacterial, antiproliferative, and chemopreventive
Ligustrum lucidum Fruit (LLF) comprehensive mechanism: four simultaneous actions, bone remodeling balance (inhibit osteoclastogenesis, promote osteoblast activity), calcium homeostasis (CaSR/PTH axis), Nox4/ROS/NF-κB antioxidant suppression, and BMSCs differentiation (inhibit adipogenesis, promote osteogenesis)
Ligustrum lucidum multi-system pharmacology: anti-inflammatory (NF-κB/MAPK/HO-1), anti-tumor (casp-3/8/9 apoptosis, PI3K/Akt/MMP2 migration), anti-osteoporosis (NFATc1/ERK osteoclasts + Wnt/β-cat/BMP osteoblasts), hepatoprotection (LXR-α/SREBP/Smad4), antioxidant (NOx4/SOD/GSH-Px), anti-depression (CaSR/TLR4/NLRP3)
FLL calcium homeostasis mechanism: kidney activation of 1,25(OH)₂D₃ → intestinal TRPV6/CaBP-9K/VDR transporter upregulation, plus gut microbiota short-chain fatty acids (SCFAs) → combined enhanced intestinal Ca²⁺ absorption → net bone calcium deposition
FLL Triterpene Structure: Oleanolic Acid Molecular Formula (C₃₀H₄₈O₃, pentacyclic triterpenoid backbone shared with ursolic acid)
FLL iridoid glycoside structures: oleoside-type iridoid variants (compounds 1–5), including salidroside-type ester and phenylalanine ester variants, key bioactive glycoside scaffolds in Ligustrum lucidum Fruit
Oleanolic acid (FLL active compound): anti-osteoclast mechanism, suppresses RANKL-induced osteoclastogenesis, blocks TRAF6/NF-κB/c-Fos/NFATc1 cascade, and supports osteoblast differentiation via BMP/Smad pathway activation
Oleanolic acid pharmacological research: bone formation pathway activation, osteoblast differentiation support, and anti-resorptive properties documented, one of the primary active triterpenoids delivered by Osstivia SNEDDS formulation
FLL Research Library
RESEARCH SNIPPETS
Direct excerpts and figures from peer-reviewed studies on Fructus Ligustri Lucidi. Click any card to expand. Use arrows or dots to browse.
Human Evidence
CLINICAL TRIAL DATA
A clinical trial involving women taking FLL powder documented significant improvements in bone mineral density. This used a basic milk powder delivery method. With SNEDDS, results are expected to be substantially superior.
0.32 g/cm2
High-Dose Group BMD
vs. control 0.26 g/cm2. Statistically significant (p less than 0.05). Leung et al. 2015
Milk Powder
Delivery Method Used
Basic oral delivery with first-pass metabolism intact. Osstivia SNEDDS bypasses this entirely for greater efficacy.
p < 0.01
Calcium Retention Significance
Both Ca absorption rate and Ca retention rate significantly improved (Chen et al. 2021)
Leung et al. 2015 clinical conclusion: rich laboratory evidence and positive clinical observations establish FLL as a safe, effective nutritional supplement for bone health, recommended as a perfect choice for bone mineral density maintenance
Leung et al. 2015 clinical trial: >0.5% increase in both hip and spine BMD after 3 months of FLL supplementation, statistically significant vs. control group, zero adverse events, no body weight gain
Biochemical markers: calcium, phosphorus, and bone turnover markers across study groups
Clinical trial conclusion: FLL supplementation produces significant improvements in BMD even with basic milk powder delivery
SNEDDS Advantage vs. Milk Powder Delivery
| Property | Milk Powder (Trial) | Osstivia SNEDDS |
|---|---|---|
| Bioavailability | Low (first-pass loss) | High (lymphatic) |
| P-gp Efflux | Active efflux intact | Inhibited |
| Compound Integrity | Degraded in gut | Protected |
| Expected Efficacy | Baseline (proven) | Significantly superior |
Bone Remodeling
THE MECHANISM
Bone tissue retains active remodeling potential throughout adulthood. Osstivia modulates multiple independent biochemical pathways that govern both bone formation and resorption simultaneously.
1
Osstivia Amplifies Growth Factor Sensitivity
FLL-treated cells are measurably more sensitive to IGF-1, TGF-β, and BMP-2 signals (GO:0071363 enrichment, one of the top FLL-enriched biological processes). Bone-forming cells respond more strongly to the growth factor environment present throughout the body, amplifying the anabolic cascade.
2
BMP/Smad Drives Hypertrophic Zone Expansion
Amplified BMP-2 signaling activates RUNX2 and Osterix in chondrocytes, driving differentiation into hypertrophic chondrocytes. FLL increases hypertrophic zone thickness by 24% to 32% in vivo, directly expanding the active growth front of bone tissue.
3
Endochondral Ossification Converts Cartilage to Bone
Hypertrophic chondrocytes mineralize their matrix. Vascular invasion follows. Osteoblasts colonize and deposit new bone. ALP cleaves pyrophosphate to enable hydroxyapatite crystal formation. Wnt/β-catenin maintains osteoblast commitment throughout the process.
4
OPG/RANKL Balance Protects New Bone
Simultaneously, FLL suppresses RANKL expression and upregulates OPG, preventing osteoclast activation and protecting newly deposited bone matrix from premature resorption. c-Fos/AP-1 and TRAF6/NF-kB suppression ensure the resorptive cascade stays suppressed throughout the remodeling cycle.
Additional Research Areas
SYSTEMIC RESEARCH
Studies of FLL and its constituent compounds also report measurements related to gut microbiota, oxidative-stress signaling, calcium regulation, immune markers, liver enzymes, and mitochondrial pathways. The summaries below describe those reported endpoints.
Gut Microbiota
Sirt6 / Oxidative Stress
Nrf2 / HO-1
Calcium Regulation
Immune Markers
Liver Markers
HPA-Axis Research
Neurobiology
GUT SUPPORT
Gut Microbiota and SCFA Measurements
Chen et al. (J Ethnopharmacol. 2021;279:114348) measured gut-microbiota composition, short-chain fatty acids, and calcium-balance markers following FLL exposure.
SIRT6, OXIDATIVE-STRESS MARKERS
Oxidative-Stress and Sirt6 Markers
Li et al. (Aging. 2019;11:9348) reported changes in Nrf2/HO-1, Sirt6, and TMAO-associated pathways in its experimental model.
CALCIUM REGULATION
Calcium Absorption and Retention
The cited study reported higher calcium absorption and retention rates (p less than 0.01) alongside measurements of PTH/VDR/TRPV6-related signaling.
IMMUNE MODULATION, Ursolic Acid
Macrophage and Cytokine Markers
Feng et al. (Front Immunol. 2025) reviewed ursolic acid in relation to TNF-alpha, IL-1beta, IL-6, NF-kB/AP-1/STAT3 signaling, and M1/M2 macrophage markers.
LIVER AND METABOLIC MARKERS, Oleanolic Acid
Oleanolic Acid and Liver Markers
HPLC analysis measures oleanolic acid at 15-20% in the formula. Studies of oleanolic acid report ALT/AST and Nrf2/ARE-associated endpoints together with lipid-metabolism markers.
NEUROBIOLOGY AND HPA-AXIS MARKERS, Salidroside
Salidroside Pathway Research
Research on salidroside includes AMPK/Sirt1/PGC-1alpha signaling, mitochondrial measures, amyloid-beta aggregation, and HPA-axis markers.
Protocol Guide
CARE AND USAGE
Osstivia is an advanced liquid formulation. How you take it, store it, and pair it matters. Follow this guide to get the most out of your protocol.
How to Take It
Take Osstivia orally via the glass dropper that comes with the bottle. The dropper is marked with precise measurements so you can easily track your daily mL dosage.
Do NOT
- x Refrigerate
- x Place near direct sunlight
- x Put in super warm liquids
- x Mix into oil
- x Shake if already diluted
You CAN
- v Take by itself or in water
- v Drink other beverages before/after
- v Shake the bottle before use (undiluted)
- v Pair with Vitamin D3, K2, and Calcium
Safety and Toxicology
Leung et al. (2015) reported zero adverse events during the 3-month clinical study. The study also tracked body weight and biochemical measures across groups.
Zero adverse events in clinical trial (Leung et al. 2015)
Taste Profile
The formula is not flavored to taste sugary or artificial. Taste responses vary, particularly with the formulation excipients.
Study Duration and Bottle Planning
The duration table above shows how bottle size and daily volume determine supply length. Studies cited on this page report outcomes over defined treatment periods, including a 3-month clinical interval.
GET OSSTIVIAOsstivia FAQ
OSSTIVIA BONE SUPPLEMENT FAQ
Clear answers for people comparing Osstivia with conventional bone supplements, mineral formulas, and botanical bone health protocols.
What is Osstivia?
Osstivia is a liquid bone supplement from OssiaLabs built around Fructus Ligustri Lucidi (FLL) and SNEDDS nano-delivery.
Is Osstivia a bone supplement?
Yes. Osstivia is positioned as a bone supplement focused on FLL bioactives, bone metabolism pathways, and support for the body's response to mechanical stimulation.
What makes it different?
Many bone supplements focus on minerals alone. Osstivia combines FLL botanical compounds with SNEDDS delivery technology designed to improve oral delivery of lipophilic bioactives.
How does SNEDDS improve bioavailability?
SNEDDS (Self Nano-Emulsifying Drug Delivery System) forms lipid droplets under 200 nm upon gastrointestinal contact. Research on this delivery platform measures dispersion, dissolution, intestinal transport, and interactions with P-glycoprotein efflux.
What is the recommended protocol?
Use the labeled serving instructions and the marked glass dropper to measure each serving. The bottle-duration table shows how long each size lasts at several daily volumes.
Is it safe?
Leung et al. (2015) reported zero adverse events during a 3-month human study of FLL powder. The study also recorded body weight and biochemical markers.
How long until I see results?
The cited clinical study reports BMD measurements after a 3-month intervention. The table above presents the observed group values and statistical results.
What does it taste like?
The formula is not flavored to taste sugary or artificial. Taste responses vary, particularly with the formulation excipients.
Can I pair it with other supplements?
The pathway references on this page include Vitamin D receptor and calcium-transport signaling. Data shows potential synergy when paired with Vitamin D3, K2, and Calcium, nutrients associated with these pathways. Avoid refrigerating or diluting in warm liquids.
Why does FLL have such a clean safety record?
Unlike synthetic pharmaceutical compounds that act as high-affinity receptor agonists, FLL bioactives engage many interconnected pathways simultaneously, with some balancing others. This distributed mechanism avoids the abrupt single-receptor intervention that typically causes drug side effects. The compounds do not overwhelm any one system. Instead, they nudge many systems toward a more favorable state in a way that the body recognises as compatible. This is why FLL's toxicology data is excellent and its safety record in clinical research is zero adverse events.
Is FLL hard on the liver?
No. At normal supplemental doses, FLL compounds are not hepatotoxic and in fact show hepatoprotective activity. Unlike many pharmaceutical bone drugs that stress hepatic metabolism, FLL bioactives including oleanolic acid and ursolic acid are documented to support liver health. The liver-safe profile is one reason FLL has centuries of traditional use and a consistently clean modern clinical record.